Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Authorship Criteria
8%
Cardiovascular History
8%
Cardiovascular Risk
8%
Clinical Data
10%
Clinical Decision Support Tool
8%
Cross-cohort
8%
Cross-sectional Observational Study
8%
Disease Duration
9%
Dopaminergic Pathway
8%
Freezing of Gait
9%
Gait Data
8%
GBA1
18%
GBA1 Variant
10%
Global Test
8%
Gut Microbiota
8%
Health Effects
8%
High-dimensional Data
8%
Hyposmia
8%
Idiopathic Parkinson's Disease
8%
Idiopathic PD
8%
Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD)
10%
Levodopa-induced Dyskinesia
17%
Long-read Sequencing
8%
Longitudinal Mixed Model
17%
Luxembourgish
9%
Machine Learning
11%
Major Risk
8%
Memory Impairment
8%
Metabolomics Data
8%
Mild Cognitive Impairment
17%
Mixed Model Analysis
17%
Non-carriers
13%
Non-motor Symptoms
16%
Outcome Prediction
8%
Parkinson
25%
Parkinson's Disease
71%
Polygenic Background
8%
Post-COVID
8%
Predictors of Cognitive Impairment
8%
Procedural Memory
9%
Prodromal Parkinson's Disease
8%
Prognostic Analysis
8%
Risk Factors
9%
Risk Variant
17%
RNA Sequencing (RNA-seq)
8%
Sex-specific
8%
Single nucleotide Polymorphism
8%
Unified Parkinson's Disease Rating Scale (UPDRS)
10%
Variant Carriers
8%
Xanthine Metabolism
8%
Neuroscience
Behavior Disorder
8%
Cardiovascular System
8%
Cognitive Disorders
9%
Comorbidity
11%
Dopamine
8%
Dyskinesia
17%
Freezing Of Gait
10%
Gait
10%
Gene Expression
8%
Genetics
10%
Gut Microbiome
17%
Hyposmia
8%
L-DOPA
17%
Memory Disorder
8%
MicroRNA
8%
Mild Cognitive Impairment
28%
Non-Motor Symptoms
11%
Parkinson's Disease
100%
Procedural Memory
9%
Progressive Supranuclear Palsy
8%
Rapid Eye Movement Sleep
8%
Regression Analysis
5%
Risk Factor
13%
RNA-Seq
8%
Medicine and Dentistry
Biological Marker
10%
Cardiovascular System
8%
Comorbidity
6%
Dopamine
8%
Education
9%
Gait
21%
Gene Expression
8%
Genetics
8%
Gut Microbiome
8%
Levodopa-Induced Dyskinesia
8%
Metabolomics
17%
Mild Cognitive Impairment
8%
Mixed Model
8%
Myelodysplastic Syndrome
8%
Observational Study
8%
Parkinson's Disease
52%
Personalized Medicine
8%
RNA Sequencing
8%
Scoping Review
9%
Tamsulosin
8%
Unified Parkinson's Disease Rating Scale
8%
